NDAINHALATIONGAS
Approved
Dec 2022
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
XENOVIEW (xenon xe 129 hyperpolarized) by Polarean Imaging is magnetic resonance contrast activity [moa]. First approved in 2022.
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XENOVIEW is a hyperpolarized xenon-129 gas inhaled as a magnetic resonance contrast agent that enables functional lung imaging. It works via magnetic resonance contrast activity to visualize pulmonary ventilation and gas exchange. This orphan-class imaging agent provides diagnostic capability for obstructive and interstitial lung diseases without ionizing radiation.
Peak9.4 years to LOE
Early-stage peak lifecycle with zero direct competitors creates acquisition and market-building opportunities, though limited published spending suggests nascent commercialization requiring specialized sales infrastructure.
Mechanism of Action
Magnetic Resonance Contrast Activity
Pharmacologic Class:
Hyperpolarized Contrast Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on XENOVIEW offers rare early-stage diagnostic platform experience in an uncontested category with strong patent protection through 2035. Roles emphasize specialized medical education, payer engagement, and clinical adoption strategy rather than competitive blocking, creating differentiated career development in precision imaging.
Medical Science Liaison (specialized imaging)
Worked on XENOVIEW at Polarean Imaging? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.